Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Kadmon Holdings Inc    KDMN

KADMON HOLDINGS INC (KDMN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/12/2018 11/13/2018 11/14/2018 11/15/2018 11/16/2018 Date
2.45(c) 2.54(c) 2.45(c) 2.57(c) 2.62(c) Last
788 163 267 256 244 157 227 629 596 149 Volume
-7.20% +3.67% -3.54% +4.90% +1.95% Change
More quotes
Financials (USD)
Sales 2018 2,06 M
EBIT 2018 -80,9 M
Net income 2018 -38,4 M
Debt 2018 -
Yield 2018 -
Sales 2019 2,24 M
EBIT 2019 -89,9 M
Net income 2019 -50,6 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 144x
Capi. / Sales2019 132x
Capitalization 296 M
More Financials
Company
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics.Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine.The company was founded by Steven... 
Sector
Pharmaceuticals
Calendar
03/20Earnings Release
More about the company
Surperformance© ratings of Kadmon Holdings Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on KADMON HOLDINGS INC
11/12KADMON : Provides Business Update and Reports Third Quarter 2018 Financial Resul..
AQ
11/09KADMON : Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/09Kadmon Provides Business Update and Reports Third Quarter 2018 Financial Resu..
GL
11/07Kadmon to Present at the Jefferies 2018 London Healthcare Conference
GL
11/06KADMON : Presents New Preclinical Data on its Immuno-Oncology Fusion Protein at ..
AQ
11/01KADMON : Announces Oral Presentation on KD025 in Chronic Graft-Versus-Host Disea..
AQ
10/26KADMON : Initiates Pivotal Phase 2 Trial of KD025 in Chronic Graft-Versus-Host D..
AQ
10/26KADMON : Initiates Pivotal Phase 2 Trial of KD025 in Chronic Graft-Versus-Host D..
AQ
10/25KADMON HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
10/25KADMON : Announces CFO Transition and Other Updates
AQ
More news
Sector news : Biopharmaceuticals
02:58pGLOBAL MARKETS LIVE : Facebook, Pfizer, Bombardier, Nissan…
02:31pMERCK : Palantir Technologies to Form JV
DJ
02:31pGLAXOSMITHKLINE : Looks to Expand Nucala Indication in the U.S.
DJ
02:06pMerck KGaA, Pfizer's Javelin Phase 3 Trial Missed Primary Endpoints
DJ
01:26pNOVARTIS : CEO Bets on Cutting-Edge Science to Remake Drug Giant
DJ
More sector news : Biopharmaceuticals
Latest Tweets
11/18Kadmon $KDMN Upgraded by Zacks Investment Research to “Buy”  
11/17Kadmon $KDMN Upgraded to “Buy” by Zacks Investment Research  
11/15Kadmon Holdings Inc Expected to Earn FY2018 Earnings of -$0.83 Per Share $KDM.. 
11/13Kadmon’s $KDMN “Buy” Rating Reaffirmed at HC Wainwright  
11/10Zacks: Analysts Anticipate Kadmon Holdings Inc $KDMN Will Post Earnings of -$.. 
More tweets
Qtime:14
News from SeekingAlpha
11/12Tracking Dan Loeb's Third Point Portfolio - Q3 2018 Update 
11/09Kadmon beats by $0.12, beats on revenue 
11/05WEEK 45 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
10/30KADMON HOLDINGS : Revaluation Opportunity Still Intriguing 
10/26Dosing underway in mid-stage study of Kadmon's KD025 in cGVHD; shares up 17% 
Chart KADMON HOLDINGS INC
Duration : Period :
Kadmon Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KADMON HOLDINGS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 10,3 $
Spread / Average Target 292%
EPS Revisions
Managers
NameTitle
Harlan W. Waksal President, Chief Executive Officer & Director
Bart M. Schwartz Chairman
John L. Ryan Chief Medical Officer & Executive Vice President
Eugene Andrew Bauer Independent Director
Dennie Dixon Boardman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KADMON HOLDINGS INC-27.62%296
BIOGEN1.72%65 290
CSL LIMITED29.99%60 533
ALEXION PHARMACEUTICALS-0.81%26 464
GRIFOLS6.45%18 191
BIOMARIN PHARMACEUTICAL7.32%17 041